Arbutus Biopharma (ABUS) Return on Sales (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Return on Sales for 14 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales rose 15.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 13.0% YoY) and the FY2025 annual result came in at 0.15%, down 4.0% from the prior year.
• Return on Sales grew to 0.01% in Q1 2026 per ABUS's latest filing, from 0.05% in the prior quarter.
• Over the last five years, Return on Sales for ABUS reached as high as 0.01% in Q1 2026 and fell as low as 0.15% in Q3 2024.
• A 5-year average of 0.06% and a median of 0.04% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales slipped 10 bps — and 2026, when it advanced 15 bps.
• Year by year, Return on Sales stood at 0.04% in 2022, then sank by 156 bps to 0.09% in 2023, then advanced by 12 bps to 0.08% in 2024, then surged by 40 bps to 0.05% in 2025, then jumped by 120 bps to 0.01% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.01%, 0.05%, and 0.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.